SenzaGen AB (SENZA.ST)
Stockholm · SEK · Healthcare · Diagnostics & Research
SEK 4.35 (-0.46%) as of
Key statistics
- Market cap
- 141.41M
- Forward P/E
- -43.50
- EPS (TTM)
- -0.3500
- Dividend yield
- 0.00%
- 52-week range
- 4.2100 – 6.8400
- Beta
- 0.60
- Revenue (TTM)
- 61.05M
- Profit margin
- -15.15%
- Volume
- 5.22k
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries. Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Lund, Sweden
- Employees
- 34
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.